Pros
Allscripts is well-positioned in a high-growth industry. Only 15% of physicians are using an EHR (our bread & butter product) and the Obama Stimulus package includes $20 Billion for physicians to encourage adoption. Allscripts positioned themselves to grab the lion-share through savvy business strategies (giving away ePrescribing to create presence in doctor's offices), key purchases of top companies whose products complimented their own and the recent Misys merger which connected them to 150,000 physicians to sell to. Glen Tullman was recognized last year as the top newsmaker in the Healthcare IT space and he is the only person from the industry who has served as advisor to President Obama on the need for healthcare automation. In my short time here I've watched him grow the company from $183MM to @ $700MM. Since his prefered reward to top performers is restricted stock, we are invested in driving this growth.
Cons
Much of Allscripts growth comes in the form of mergers and acquisitions. Some of these are easier then other and the results are conflicts in culture and pockets of "us vs. them" attitudes which are at best annoying and at worst harmful to progress. This is likely confusing to new hires if their team insists on calling products by their old names or citing the wisdom of former owners. More attention to blending cultures must be paid. Rapid growth companies are not for everybody. We do work hard here to make it happen.